Stryker Corporation (SYK) — ESG & Values Scores

Environment story

Stryker's 10-K does not disclose Scope 1, 2, or 3 emissions figures, a net-zero target year, or renewable-electricity percentage, triggering deductions for non-disclosure. The filing references potential regulatory scrutiny of per- and polyfluoroalkyl substances (PFAS) in device manufacturing/sterilization as an emerging environmental compliance risk, but no quantified toxic-waste or water-consumption controversy with a verified source is documented. No verified capital investment in physical decarbonization infrastructure (e.g., renewable energy generation, electrified fleets) is disclosed in the filing. This is descriptive research output, not investment advice.

Criticisms on file

Governmental authorities in the U.S. and internationally are considering new regulations on per- and polyfluoroalkyl substances (PFAS) used in manufacturing/sterilization processes, indicating potential unmitigated chemical/environmental compliance exposure.
Source: SYK_10k.txt (Item 1A Risk Factors)

Disclosed initiatives

No disclosed initiatives on file for this pillar.

Social story

The 10-K and proxy do not disclose a specific CEO-to-median-worker pay ratio figure, plant safety metrics, turnover rate, or supply-chain human-rights audit results, so no deterministic penalty was applied for these categories absent verified data. Board-level gender diversity is approximately 50% (5 of 10 director nominees are women), which is above the 30% threshold used in this rubric. No documented union-suppression activity, NLRB complaints, or major strikes within the last 24 months were identified in the source filings; the 10-K notes generic risk language around 'increased unionization' as a potential future cost factor, but this is not evidence of active suppression. This is descriptive research output, not investment advice.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Human Capital Management Board Oversight

Multiple director nominees identified with Human Capital Management as a listed skill/expertise area in the proxy skills matrix.

Governance story

Stryker maintains a single-class common share structure (no dual-class voting disclosed) and reports that all directors are independent other than the combined Chair/CEO, i.e., approximately 90% board independence, above the 75% threshold. No active lobbying specifically targeting climate or consumer-protection deregulation was disclosed. However, the company has a documented history of FCPA-related SEC settlements (2013, 2018) with fines and a retained independent compliance consultant, plus a since-closed 2025-2026 DOJ/SEC inquiry into additional potential FCPA matters, an unresolved German tax audit assessment (~$754 plus $11 in additional assessments), and multiple ongoing product-liability lawsuits (Rejuvenate, ABGII Modular-Neck, LFIT V40, Wright legacy hip products) — collectively treated as active regulatory/legal proceedings warranting a moderate deduction. This is descriptive research output, not investment advice.

Criticisms on file

2013 and 2018 SEC settlements related to Foreign Corrupt Practices Act (FCPA) violations, resulting in fines and an independent compliance consultant.
Source: SYK_10k.txt (Item 1A Risk Factors, Legal and Regulatory Risks)
DOJ and SEC investigations into whether business activities in certain foreign countries violated FCPA and analogous local laws; both agencies closed their inquiries in 2025/2026, with company still responding to related inquiries by foreign authorities.
Source: SYK_10k.txt (Item 1A Risk Factors)
German Federal Central Tax Office (FCTO) final audit report and assessment of $754 (plus expected additional $11) covering tax years 2010-2017, under appeal/litigation.
Source: SYK_10k.txt (MD&A, Critical Accounting Policies)
Ongoing product liability litigation involving Rejuvenate and ABGII Modular-Neck hip stems, LFIT Anatomic CoCr V40 Femoral Heads, and Wright Medical Group legacy hip products.
Source: SYK_10k.txt (Item 1A Risk Factors; Note 7 reference)

Disclosed initiatives

No Poison Pill / Proxy Access / Majority Voting

Company maintains majority voting with resignation policy in uncontested elections, proxy access rights for shareholders, shareholder right to call special meetings, and no poison pill takeover defense.

Enhances shareholder rights and reduces entrenchment risk.
Clawback and Recoupment Policies

Mandatory clawback policy (adopted October 2023) for accounting restatements per SEC/Dodd-Frank rules, plus broader recoupment policy applying to cash and equity incentive awards for officers since 2014.

Strengthens executive accountability.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Stryker Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Stryker Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)